Theratechnologies Gains Support for Future Pak Acquisition
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Theratechnologies ( (TSE:TH) ) is now available.
Theratechnologies Inc. announced that independent proxy advisory firms ISS and Glass Lewis have recommended shareholders vote in favor of a proposed plan of arrangement with Future Pak. The arrangement involves the acquisition of all issued and outstanding shares of Theratechnologies by CB Biotechnology, an affiliate of Future Pak, for a cash consideration of US$3.01 per share, plus contingent value rights. The board of directors unanimously supports the arrangement, citing a robust process and credible valuation, and encourages shareholders to vote in favor of the proposal at the upcoming special meeting.
The most recent analyst rating on (TSE:TH) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies’ overall score is driven by positive corporate events, including a favorable acquisition agreement, which boosts shareholder value. Strong technical indicators also support the stock’s outlook. However, financial performance and valuation challenges, such as negative equity and a lack of profitability, weigh on the score.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The company operates in the pharmaceutical industry, with a market focus on biopharmaceutical products.
Average Trading Volume: 52,100
Technical Sentiment Signal: Hold
Current Market Cap: C$204.6M
See more data about TH stock on TipRanks’ Stock Analysis page.
